CY1120338T1 - Εκλεκτικοι ρυθμιστες υποδοχεα φωσφορικης σφιγγοσινης 1 και μεθοδοι χειρομορφικης συνθεσης - Google Patents
Εκλεκτικοι ρυθμιστες υποδοχεα φωσφορικης σφιγγοσινης 1 και μεθοδοι χειρομορφικης συνθεσηςInfo
- Publication number
- CY1120338T1 CY1120338T1 CY20181100611T CY181100611T CY1120338T1 CY 1120338 T1 CY1120338 T1 CY 1120338T1 CY 20181100611 T CY20181100611 T CY 20181100611T CY 181100611 T CY181100611 T CY 181100611T CY 1120338 T1 CY1120338 T1 CY 1120338T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- sphygesin
- chirmorphic
- receptors
- phosphoric
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
- C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Oncology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Παρέχονται ενώσεις οι οποίες εκλεκτικώς ρυθμίζουν τον υποδοχέα φωσφορικής σφιγγοσίνης 1 που περιλαμβάνουν ενώσεις που ρυθμίζουν τον υπότυπο 1 του SIP υποδοχέα. Παρέχονται μέθοδοι χειρομορφικής σύνθεσης τέτοιων ενώσεων. Χρήσεις, μέθοδοι θεραπείας ή πρόληψης και μέθοδοι παρασκευής συνθέσεων της εφεύρεσης, συμπεριλαμβανομένων ενώσεων της εφεύρεσης, παρέχονται σε συνδυασμό με τη θεραπεία ή πρόληψη ασθενειών, δυσλειτουργιών και διαταραχών για τις οποίες ρύθμιση του υποδοχέα φωσφορικής σφιγγοσίνης 1 ιατρικώς ενδείκνυται.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26130109P | 2009-11-13 | 2009-11-13 | |
US26247409P | 2009-11-18 | 2009-11-18 | |
PCT/US2010/056760 WO2011060392A1 (en) | 2009-11-13 | 2010-11-15 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120338T1 true CY1120338T1 (el) | 2019-07-10 |
Family
ID=43992106
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100611T CY1120338T1 (el) | 2009-11-13 | 2018-06-12 | Εκλεκτικοι ρυθμιστες υποδοχεα φωσφορικης σφιγγοσινης 1 και μεθοδοι χειρομορφικης συνθεσης |
CY2020035C CY2020035I2 (el) | 2009-11-13 | 2020-11-19 | Εκλεκτικοι ρυθμιστες υποδοχεα φωσφορικης σφιγγοσινης 1 και μεθοδοι χειρομορφικης συνθεσης |
CY20211100241T CY1124121T1 (el) | 2009-11-13 | 2021-03-22 | Εκλεκτικοι ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφικης συνθεσης |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2020035C CY2020035I2 (el) | 2009-11-13 | 2020-11-19 | Εκλεκτικοι ρυθμιστες υποδοχεα φωσφορικης σφιγγοσινης 1 και μεθοδοι χειρομορφικης συνθεσης |
CY20211100241T CY1124121T1 (el) | 2009-11-13 | 2021-03-22 | Εκλεκτικοι ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφικης συνθεσης |
Country Status (30)
Country | Link |
---|---|
US (4) | US8362048B2 (el) |
EP (3) | EP3868377A1 (el) |
JP (3) | JP5650233B2 (el) |
KR (2) | KR101721716B1 (el) |
CN (2) | CN102762100B (el) |
AU (1) | AU2010319983B2 (el) |
BR (2) | BR112012011427B8 (el) |
CA (2) | CA2986521C (el) |
CY (3) | CY1120338T1 (el) |
DK (2) | DK3406142T3 (el) |
EA (2) | EA024801B1 (el) |
ES (2) | ES2673160T3 (el) |
FR (1) | FR20C1059I2 (el) |
HK (2) | HK1213874A1 (el) |
HR (2) | HRP20180874T1 (el) |
HU (3) | HUE037535T2 (el) |
IL (2) | IL219691B (el) |
LT (3) | LT3406142T (el) |
MX (1) | MX2012005560A (el) |
MY (2) | MY189750A (el) |
NO (2) | NO2498610T3 (el) |
NZ (1) | NZ599915A (el) |
PH (1) | PH12015502708B1 (el) |
PL (2) | PL3406142T3 (el) |
PT (2) | PT2498610T (el) |
RS (2) | RS61829B1 (el) |
SG (1) | SG10201407357PA (el) |
SI (2) | SI3406142T1 (el) |
TR (1) | TR201807912T4 (el) |
WO (1) | WO2011060392A1 (el) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102724880B (zh) * | 2009-11-13 | 2016-09-14 | 瑞塞普托斯有限责任公司 | 1-磷酸鞘氨醇受体调节剂及手性合成方法 |
PL3406142T3 (pl) | 2009-11-13 | 2021-08-30 | Receptos Llc | Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej |
EP2706999B1 (en) | 2011-05-13 | 2019-08-28 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
NZ702974A (en) * | 2012-06-21 | 2016-03-31 | Eisai R&D Man Co Ltd | Novel indanesulfamide derivative |
WO2014158302A1 (en) * | 2013-03-25 | 2014-10-02 | Swenson Rolf Eric | Novel sphingosine 1-phosphate receptor antagonists |
US20170165236A1 (en) * | 2013-11-01 | 2017-06-15 | Celgene International Ii Sàrl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
US20180016244A1 (en) | 2015-04-06 | 2018-01-18 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
US11111223B2 (en) | 2016-06-14 | 2021-09-07 | Receptos Llc | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
US11192886B2 (en) | 2016-07-22 | 2021-12-07 | Medshine Discovery Inc. | S1P1 agonist and application thereof |
WO2018033149A1 (zh) * | 2016-08-19 | 2018-02-22 | 苏州科睿思制药有限公司 | 奥扎莫德的晶型及其制备方法 |
WO2018049632A1 (zh) * | 2016-09-14 | 2018-03-22 | 杭州领业医药科技有限公司 | 奥扎莫德的晶型、其制备方法及药物组合物 |
CN109640982A (zh) * | 2016-09-14 | 2019-04-16 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
WO2018064356A1 (en) | 2016-09-29 | 2018-04-05 | Celgene International Ii Sarl | Compounds and methods for treating lupus |
US10981900B2 (en) * | 2017-02-28 | 2021-04-20 | Medshine Discovery Inc. | Spiro compound and use thereof |
CN110612292A (zh) * | 2017-04-07 | 2019-12-24 | 杭州领业医药科技有限公司 | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 |
CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
CN108727292A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 一种奥扎莫德及其中间体的制备方法 |
EP3621610A1 (en) | 2017-05-08 | 2020-03-18 | Celgene International II Sàrl | Sphingosine 1 phosphate receptor agonists for neuroprotection |
EP3630738B1 (en) * | 2017-05-22 | 2023-07-19 | Egis Gyógyszergyár Zrt. | Process for the production of ozanimod |
US10278960B2 (en) | 2017-06-23 | 2019-05-07 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
CN109280035B (zh) * | 2017-07-19 | 2023-06-09 | 广东东阳光药业有限公司 | 奥扎莫德的多晶型及其制备方法 |
US11117876B2 (en) | 2017-08-31 | 2021-09-14 | Receptos Llc | Crystalline form of ozanimod hydrochloride, and processes for preparation thereof |
WO2019058290A1 (en) * | 2017-09-20 | 2019-03-28 | Suven Life Sciences Limited | IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND |
WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
CN107857760A (zh) * | 2017-11-21 | 2018-03-30 | 南京天翔医药科技有限公司 | 鞘氨醇‑1‑磷酸受体调节剂及其应用 |
EP3741755A4 (en) * | 2018-01-18 | 2021-09-01 | Shijiazhuang Sagacity New Drug Development Company, Ltd. | CRYSTALLINE AND SALINE FORMS OF TRICYCLIC COMPOUNDS AND THEIR PREPARATION PROCESS |
MX2020009100A (es) | 2018-03-20 | 2020-12-03 | Eisai R&D Man Co Ltd | Agente de tratamiento de la epilepsia. |
CN110615747A (zh) * | 2018-06-20 | 2019-12-27 | 广东东阳光药业有限公司 | 一种二氢茚中间体的制备方法 |
WO2020053334A1 (en) | 2018-09-12 | 2020-03-19 | Pharmazell Gmbh | A process for the preparation of ozanimod and its intermediate (s)-1-amino-2,3-dihydro-1h-indene-4-carbonitrile |
AR116479A1 (es) | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
US11390593B2 (en) | 2018-12-07 | 2022-07-19 | Synthon B.V. | Process for preparing ozanimod |
US20220194971A1 (en) * | 2019-03-29 | 2022-06-23 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
JP2022528001A (ja) * | 2019-03-29 | 2022-06-07 | レセプトス・リミテッド・ライアビリティ・カンパニー | スフィンゴシン1リン酸受容体調節因子 |
KR20210151067A (ko) * | 2019-03-29 | 2021-12-13 | 리셉토스 엘엘씨 | 스핑고신 1 포스페이트 수용체 조절제 |
EP3959204A4 (en) * | 2019-04-26 | 2022-12-28 | Receptos Llc | SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR |
CN112062785B (zh) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | 奥扎莫德及其中间体的制备方法 |
MX2022000651A (es) | 2019-07-16 | 2022-03-11 | Synthon Bv | Proceso mejorado para preparar ozanimod. |
CN114599363A (zh) | 2019-10-31 | 2022-06-07 | 爱杜西亚药品有限公司 | Cxcr7拮抗剂与s1p1受体调节剂的组合 |
US20230338336A1 (en) * | 2020-01-06 | 2023-10-26 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
EP4116295A4 (en) * | 2020-03-04 | 2023-08-02 | Helioeast Pharmaceutical Co., Ltd. | TRICYCLIC COMPOUNDS AND THEIR USE |
WO2021175223A1 (zh) * | 2020-03-04 | 2021-09-10 | 南京明德新药研发有限公司 | 苯并2-氮杂螺[4.4]壬烷类化合物及其应用 |
CA3172272A1 (en) | 2020-03-17 | 2021-09-23 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of coronavirus infection |
WO2021197852A1 (en) | 2020-04-02 | 2021-10-07 | Synthon B.V. | Crystalline form of ozanimod hydrochloride |
CN111620788B (zh) * | 2020-04-20 | 2022-09-30 | 广东莱佛士制药技术有限公司 | 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法 |
EP4321507A1 (en) * | 2021-04-09 | 2024-02-14 | Helioeast Pharmaceutical Co., Ltd. | Oxadiazole-substituted spirocyclic compound and application thereof |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
FR2628103B1 (fr) * | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
US5039802A (en) | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
WO1992018462A1 (en) | 1991-04-12 | 1992-10-29 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
GB2290790A (en) | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
ATE249455T1 (de) * | 1998-01-23 | 2003-09-15 | Sankyo Co | Spiropiperidin-derivate |
US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
JP4516430B2 (ja) | 2002-12-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 1−(アミノ)インダン並びに(1,2−ジヒドロ−3−アミノ)−ベンゾフラン、ベンゾチオフェン及びインドール |
BRPI0409319B8 (pt) | 2003-04-11 | 2021-05-25 | Ptc Therapeutics Inc | composto, composição farmacêutica, forma de dosagem unitária, e, uso de um composto |
CA2539438A1 (en) * | 2003-10-01 | 2005-04-14 | Merck And Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
AU2004299456B2 (en) * | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
JP2008531546A (ja) | 2005-02-22 | 2008-08-14 | テバ ファーマシューティカル インダストリーズ リミティド | エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス |
KR100667075B1 (ko) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치 |
EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
PE20070705A1 (es) * | 2005-11-25 | 2007-08-23 | Basf Ag | Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales |
EP1963509A4 (en) | 2005-12-21 | 2009-07-29 | Joseph Gabriele | CATECHOLAMINE-REGULATED PROTEIN |
JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | H3受容体のテトラリン拮抗薬 |
US20080009534A1 (en) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
AU2007298593A1 (en) * | 2006-09-21 | 2008-03-27 | Actelion Pharmaceuticals Ltd | Phenyl derivatives and their use as immunomodulators |
AU2007323540A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
MX2009006304A (es) | 2006-12-15 | 2009-06-23 | Abbott Lab | Nuevos compuestos de oxadiazol. |
JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
WO2008143730A2 (en) | 2007-02-28 | 2008-11-27 | Rib-X Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
WO2009131090A1 (ja) | 2008-04-21 | 2009-10-29 | 旭化成ファーマ株式会社 | アミノ酸化合物 |
EA021672B1 (ru) | 2008-05-14 | 2015-08-31 | Дзе Скриппс Рисёч Инститьют | Модуляторы рецепторов сфингозин-1-фосфата и их применение |
US8485794B2 (en) * | 2008-06-13 | 2013-07-16 | Doowon Technical College | Reciprocating compressor with rotary valve |
GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
GB0911130D0 (en) | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
PL3406142T3 (pl) | 2009-11-13 | 2021-08-30 | Receptos Llc | Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej |
MX2012005559A (es) | 2009-11-13 | 2012-08-23 | Receptos Inc | Moduladores heterociclicos selectivos del receptor de esfingosina 1 fosfato. |
CN102724880B (zh) | 2009-11-13 | 2016-09-14 | 瑞塞普托斯有限责任公司 | 1-磷酸鞘氨醇受体调节剂及手性合成方法 |
EP2706999B1 (en) | 2011-05-13 | 2019-08-28 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
-
2010
- 2010-11-15 PL PL18160667T patent/PL3406142T3/pl unknown
- 2010-11-15 DK DK18160667.4T patent/DK3406142T3/da active
- 2010-11-15 RS RS20210360A patent/RS61829B1/sr unknown
- 2010-11-15 EP EP20215106.4A patent/EP3868377A1/en not_active Withdrawn
- 2010-11-15 CA CA2986521A patent/CA2986521C/en active Active
- 2010-11-15 CN CN201080061144.8A patent/CN102762100B/zh active Active
- 2010-11-15 SI SI201032063T patent/SI3406142T1/sl unknown
- 2010-11-15 ES ES10830880.0T patent/ES2673160T3/es active Active
- 2010-11-15 CN CN201510295907.XA patent/CN105061350B/zh active Active
- 2010-11-15 EA EA201290323A patent/EA024801B1/ru not_active IP Right Cessation
- 2010-11-15 EP EP10830880.0A patent/EP2498610B1/en active Active
- 2010-11-15 NO NO10830880A patent/NO2498610T3/no unknown
- 2010-11-15 PT PT108308800T patent/PT2498610T/pt unknown
- 2010-11-15 RS RS20180647A patent/RS57253B1/sr unknown
- 2010-11-15 JP JP2012539065A patent/JP5650233B2/ja active Active
- 2010-11-15 HU HUE10830880A patent/HUE037535T2/hu unknown
- 2010-11-15 BR BR112012011427A patent/BR112012011427B8/pt active IP Right Grant
- 2010-11-15 MY MYPI2016002092A patent/MY189750A/en unknown
- 2010-11-15 US US12/946,819 patent/US8362048B2/en active Active
- 2010-11-15 EA EA201690391A patent/EA035768B1/ru not_active IP Right Cessation
- 2010-11-15 LT LTEP18160667.4T patent/LT3406142T/lt unknown
- 2010-11-15 ES ES18160667T patent/ES2858337T3/es active Active
- 2010-11-15 SI SI201031704T patent/SI2498610T1/en unknown
- 2010-11-15 LT LTEP10830880.0T patent/LT2498610T/lt unknown
- 2010-11-15 PT PT181606674T patent/PT3406142T/pt unknown
- 2010-11-15 SG SG10201407357PA patent/SG10201407357PA/en unknown
- 2010-11-15 HU HUE18160667A patent/HUE054000T2/hu unknown
- 2010-11-15 BR BR122018077504A patent/BR122018077504B8/pt active IP Right Grant
- 2010-11-15 PL PL10830880T patent/PL2498610T3/pl unknown
- 2010-11-15 MY MYPI2012002084A patent/MY161854A/en unknown
- 2010-11-15 CA CA2780772A patent/CA2780772C/en active Active
- 2010-11-15 TR TR2018/07912T patent/TR201807912T4/tr unknown
- 2010-11-15 MX MX2012005560A patent/MX2012005560A/es active IP Right Grant
- 2010-11-15 KR KR1020127015292A patent/KR101721716B1/ko active IP Right Grant
- 2010-11-15 KR KR1020167035297A patent/KR101752124B1/ko active IP Right Grant
- 2010-11-15 NZ NZ599915A patent/NZ599915A/en unknown
- 2010-11-15 AU AU2010319983A patent/AU2010319983B2/en active Active
- 2010-11-15 DK DK10830880.0T patent/DK2498610T3/en active
- 2010-11-15 EP EP18160667.4A patent/EP3406142B8/en active Active
- 2010-11-15 WO PCT/US2010/056760 patent/WO2011060392A1/en active Application Filing
-
2012
- 2012-05-09 IL IL219691A patent/IL219691B/en active IP Right Grant
-
2013
- 2013-01-14 US US13/740,661 patent/US20130231326A1/en not_active Abandoned
- 2013-03-14 HK HK16100726.3A patent/HK1213874A1/zh unknown
- 2013-03-14 HK HK13103206.9A patent/HK1175948A1/xx unknown
- 2013-11-14 JP JP2013235966A patent/JP5982705B2/ja active Active
-
2014
- 2014-11-12 JP JP2014229895A patent/JP2015038145A/ja active Pending
-
2015
- 2015-02-26 US US14/632,675 patent/US9388147B2/en active Active
- 2015-12-04 PH PH12015502708A patent/PH12015502708B1/en unknown
-
2017
- 2017-01-13 US US15/406,128 patent/US10239846B2/en active Active
-
2018
- 2018-06-05 HR HRP20180874TT patent/HRP20180874T1/hr unknown
- 2018-06-12 CY CY20181100611T patent/CY1120338T1/el unknown
-
2019
- 2019-07-09 IL IL267956A patent/IL267956B/en active IP Right Grant
-
2020
- 2020-11-18 HU HUS2000045C patent/HUS2000045I1/hu unknown
- 2020-11-18 LT LTPA2020533C patent/LTC2498610I2/lt unknown
- 2020-11-18 FR FR20C1059C patent/FR20C1059I2/fr active Active
- 2020-11-18 NO NO2020039C patent/NO2020039I1/no unknown
- 2020-11-19 CY CY2020035C patent/CY2020035I2/el unknown
-
2021
- 2021-03-17 HR HRP20210446TT patent/HRP20210446T1/hr unknown
- 2021-03-22 CY CY20211100241T patent/CY1124121T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120338T1 (el) | Εκλεκτικοι ρυθμιστες υποδοχεα φωσφορικης σφιγγοσινης 1 και μεθοδοι χειρομορφικης συνθεσης | |
CY1120427T1 (el) | Ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφης συνθεσης | |
CY1123338T1 (el) | Νεοι ρυθμιστες υποδοχεων φωσφορικης σφιγγοσινης | |
PH12020551208A1 (en) | Compounds for the treatment of kinase-dependent disorders | |
CY1115826T1 (el) | Μεσα για τη θεραπεια διαταραχων οι οποιες εμπλεκουν τη ρυθμιση των υποδοχεων ρυανοδινης | |
CY1120297T1 (el) | Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων | |
CY1118691T1 (el) | Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης | |
EA201100133A1 (ru) | Антагонисты рецепторов простагландина d | |
CY1113975T1 (el) | Παραγοντες για προληψη και θεραπεια διαταραχων που περιλαμβανουν διαφοροποιηση των υποδοχεων ryr | |
EA201001253A1 (ru) | N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d | |
CY1113798T1 (el) | Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης | |
CO6351788A2 (es) | Derivados de isoxazolo piridina | |
EA201171063A1 (ru) | Фармацевтические составы олмесартана | |
MY149855A (en) | Benzimidazole derivatives and their use for modulating the gaba? receptor complex | |
CY1117706T1 (el) | Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac | |
CY1112724T1 (el) | Παραγωγα ανθρακικης κουινουκλιδινης και ιατρικη συνθεση αυτων | |
CY1116452T1 (el) | Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης | |
CY1118966T1 (el) | Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος | |
MY169497A (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
MY147649A (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
MX2022014351A (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas. | |
CY1121898T1 (el) | Ενωσεις αμιδιου ως αγωνιστες tου υποδοχεα 5-ht4 | |
DE602007006328D1 (de) | 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren | |
CY1116158T1 (el) | Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 |